Skip to content
DataLookout
Menu

EXPrESSIVE-18NCT07850609

A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Trial sites expanded: 0 → 7 locations
    • Start date changed from estimate of Oct 29, 2026 to Oct 27, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 4 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 2 months

Secondary (6)

Maximum Plasma Concentration (Cmax) of Alimatravir in Plasma
Time to Maximum Plasma Concentration (Tmax) of Alimatravir in Plasma
Plasma Trough Concentration (Ctrough) of Alimatravir
Plasma Estradiol Concentration
Plasma Testosterone Concentration
Show 1 moreShow less
Plasma Dihydrotestosterone Concentration

Arms and interventions

AlimatravirExperimental

Alimatravir 11 mg will be taken once monthly (qm)

Drugs: Alimatravir

Sites

7 sites in 2 countries

United States 4, Canada 3